News - Advair, Pharmaceutical


Current filters:


Popular Filters

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay


The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

Generic risk to GSK's Advair prompts buy recommendation from analysts


Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

Great expectations for GlaxoSmithKline R&D newsflow


Essentially, analysts at Panmure Gordon & Co anticipate a lot of pipeline newsflow from UK pharma giant…


Asthma preventive drugs market led by GlaxoSmithKline's Advair


The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

AdvairAstraZenecaGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicort

New LABA/LAMA drugs set to fracture COPD market


The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Relovair COPD and asthma filings on track despite more mixed trial results


As well as announcing new mixed clinical trial data, UK pharma giant GlaxoSmithKline (LSE: GSK) and US…

AdvairEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRelovairRespiratory and PulmonaryTheravance

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top